Hd-EEG for Parkinson's (NCT06640673)

Detect thinking decline using recordings

Trial ID
NCT06640673
Official Title
Electrophysiological Signature of Mild Cognitive Impairment and Its Relationship with Parkinson's Disease: a High-density EEG Investigation
Goal
Detect thinking decline using recordings
Status
RECRUITING
Sponsor
IRCCS San Camillo, Venezia, Italy
Study Type
OBSERVATIONAL
Enrollment
42 participants
Conditions
Parkinson Disease, Parkinson Disease, Mild Cognitive Impairment, Healthy
Interventions
Hd-EEG

Summary For Families

The team wants to identify an electrical brain signature that marks mild cognitive impairment in people with Parkinson's and to compare those signals with healthy aging. They will record high-density EEG, which maps brain electrical rhythms across many scalp sites to detect subtle slowing or connectivity changes, and because the work is observational it does not change treatment so participants may be taking stable doses of levodopa, antidepressants, or cholinesterase drugs. They are enrolling adults 50 to 90 who can walk independently, who do not have severe dementia and have relatively preserved cognition on screening (MMSE >24 or MoCA >15.5), with any Parkinson's or related medications kept stable for at least four weeks.

Locations

  • IRCCS San Camillo S.R.L, Lido, Italy, Italy

Frequently Asked Questions

What is this trial testing?
This trial is studying Hd-EEG. The team wants to identify an electrical brain signature that marks mild cognitive impairment in people with Parkinson's and to compare those signals with healthy aging. They will record high-density EEG, which maps brain electrical rhythms across many scalp sites to detect subtle slowing or connectivity changes, and because the work is observational it does not change treatment so participants may be taking stable doses of levodopa, antidepressants, or cholinesterase drugs. They are enrolling adults 50 to 90 who can walk independently, who do not have severe dementia and have relatively preserved cognition on screening (MMSE >24 or MoCA >15.5), with any Parkinson's or related medications kept stable for at least four weeks.
Who can participate?
Participants must be between 50 Years and 90 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
How long does the trial last?
This trial is estimated to last approximately 1 year and 5 months.
Can I leave the trial if I change my mind?
Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
Can my spouse or care partner come with me to visits?
In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
Will I get a placebo in this trial?
This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
What procedures are involved in this trial?
Based on the protocol, this trial involves: Brain wave recording (EEG) (non-invasive); Thinking & memory tests (non-invasive); MRI scan (non-invasive). Confirm the full schedule with the study coordinator.

Related Reading

View on ClinicalTrials.gov